| Bioactivity | VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research[1]. |
| Sequence | Lys-Gln-Leu-Val-Ile-Lys-Pro-His-Gly-Gln-Ile-Leu-Met-Ile-Arg-Tyr-Pro-Ser-Ser-Gln-Leu-Glu-Met |
| Shortening | KQLVIKPHGQILMIRYPSSQLEM |
| Formula | C122H205N33O32S2 |
| Molar Mass | 2710.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Farzaneh Behelgardi M, et al. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis[J]. Scientific reports, 2018, 8(1): 17924. |